GlassScriptPhysician profile
Audrey Halpern
NPI 1558342261
$225,839.35
in general payments reported to CMS, 2019-2025
40 companies · $74K in 2025
The $74K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53K · 2020: $33K · 2021: $44K · 2022: $16K · 2023: $4,102 · 2024: $2,273 · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $56K · Consulting Fee: $10K · Food and Beverage: $8,090 · Travel and Lodging: $4,619 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $56,027.00 |
| Consulting Fee | $10,332.37 |
| Food and Beverage | $8,090.37 |
| Travel and Lodging | $4,618.93 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,537.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $47,974.89 | 2025 | Symbravo, Sunosi |
| Amgen INC. | $30,861.97 | 2019-2023 | Aimovig |
| Lilly USA, LLC | $28,198.06 | 2019-2025 | Emgality, Zepbound, Mounjaro |
| Lundbeck LLC | $25,552.54 | 2020-2025 | Vyepti |
| Abbvie INC. | $21,919.95 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $21,732.10 | 2021 | |
| Allergan, INC. | $21,694.02 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $14,738.43 | 2019-2025 | Ajovy |
| Biohaven Pharmaceutical Holding Company LTD. | $6,802.45 | 2022 | |
| Eli Lilly and Company | $1,264.27 | 2019 | |
| Pfizer INC. | $1,133.06 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $961.19 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $890.53 | 2019-2023 | |
| Amneal Pharmaceuticals LLC | $212.08 | 2019-2020 | |
| Assertio Therapeutics, INC. | $203.87 | 2019-2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Halpern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.